Tremelimumab

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 712 publications

A Case of Simultaneous Resection of Single Lung and Liver Metastases with Combined Immunotherapy after Radical Surgery for Hepatocellular Carcinoma

A Case of Simultaneous Resection of Single Lung and Liver Metastases with Combined Immunotherapy after Radical Surgery for Hepatocellular Carcinoma

Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: January 17, 2026

Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study.

Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: December 09, 2025

Immune Checkpoint Inhibitor-Related Hypophysitis and Pituitary Dysfunction: A Systematic Review of Diagnosis and Management.

Immune Checkpoint Inhibitor-Related Hypophysitis and Pituitary Dysfunction: A Systematic Review of Diagnosis and Management.

Journal: Cureus
Published: December 08, 2025

Efficacy and Pulmonary Outcomes of Dual Immunotherapy Plus Chemotherapy Versus Standard Chemotherapy in Advanced Non-small Cell Lung Cancer.

Efficacy and Pulmonary Outcomes of Dual Immunotherapy Plus Chemotherapy Versus Standard Chemotherapy in Advanced Non-small Cell Lung Cancer.

Journal: Cureus
Published: November 29, 2025

LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers.

LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers.

Journal: Future oncology (London, England)
Published: November 24, 2025

Successful Treatment of Nivolumab Plus Ipilimumab After Progression on Durvalumab Plus Tremelimumab in Advanced Hepatocellular Carcinoma: A Case Report.

Successful Treatment of Nivolumab Plus Ipilimumab After Progression on Durvalumab Plus Tremelimumab in Advanced Hepatocellular Carcinoma: A Case Report.

Journal: Cureus
Published: November 22, 2025

Health-Related Quality of Life in the Era of Immune Checkpoint Blockade: What Do Patient-Reported Outcomes Reveal?

Health-Related Quality of Life in the Era of Immune Checkpoint Blockade: What Do Patient-Reported Outcomes Reveal?

Journal: Cancers
Published: November 16, 2025

Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.

Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.

Journal: British journal of cancer
Published: November 11, 2025

Navigating the Therapeutic Pathway and Optimal First-Line Systemic Therapy for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors.

Navigating the Therapeutic Pathway and Optimal First-Line Systemic Therapy for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors.

Journal: Medicina (Kaunas, Lithuania)
Published: November 08, 2025

Tremelimumab Plus Durvalumab in Advanced Hepatocellular Carcinoma Treatment: A Pharmacovigilance Comparative Analysis Between Eudravigilance and HIMALAYA Study.

Tremelimumab Plus Durvalumab in Advanced Hepatocellular Carcinoma Treatment: A Pharmacovigilance Comparative Analysis Between Eudravigilance and HIMALAYA Study.

Journal: Hospital pharmacy
Published: November 04, 2025

Immune-related adverse events in hepatocellular carcinoma: organ-specific patterns and management approaches.

Immune-related adverse events in hepatocellular carcinoma: organ-specific patterns and management approaches.

Journal: Journal of liver cancer
Published: October 31, 2025

Checkpoint Inhibitor-Associated Myasthenia-Myositis Overlap With Neuromuscular Respiratory Failure After Dual PD-L1 Plus CTLA-4 Checkpoint Blockade for Hepatocellular Carcinoma.

Checkpoint Inhibitor-Associated Myasthenia-Myositis Overlap With Neuromuscular Respiratory Failure After Dual PD-L1 Plus CTLA-4 Checkpoint Blockade for Hepatocellular Carcinoma.

Journal: Cureus
Published: September 26, 2025
Showing 1-12 of 712

Last Updated: 02/24/2026